Chemokine Responses to Hepatitis C Virus and Their Impact in Mediating the Treatment Responses of Antiviral Treatment by Jon Florholmen & Rasmus Goll
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
8 
Chemokine Responses to Hepatitis C Virus and 
Their Impact in Mediating the Treatment 
Responses of Antiviral Treatment 
Jon Florholmen and Rasmus Goll  
Research group of Gastroenterology and Nutrition,  
Institute of Clinical Medicine, University of Tromsø, Tromsø  
Department of Medical Gastroenterology,  
University Hospital North Norway, Tromsø, 
Norway 
1. Introduction  
The hepatitis C virus (HCV) is a global health challenge with strong regional implications 
(Shepard et al, 2005). Currently, about 170 million people throughout the world are 
chronically HCV infected and it is the most important cause of liver disease worldwide. 
During the last 30 years the mode of transmission in industrial countries has changed from 
infection by medical use of contaminated blood products to infection by shared utensils by 
drug abusers. The incidence of HCV infection in Europe increased during the 1990`s 
(Rantala & van de Laar, 2008). It is unknown if this trend of increased incidence in Europe 
and worldwide has persisted after 2000. 
Following acute HCV infection approximately 80 % of adults and between 50 to 60% of 
children develop chronic disease (Vogt et al, 1999). The reasons for the ineffective clearance 
of HCV virus is unknown, but most likely there are viral escape factors and host factors 
such as inappropriate immune based viral clearance. Progression of chronic HCV infection 
occurs in a proportion of infected subjects in a sequence via liver fibrosis to liver cirrhosis 
and finally death due either to liver failure or to hepatocellular carcinoma (HCC). The rate 
of progression is affected by various factors such as age at infection, gender, alcohol 
consumption, and co-infection particularly with human immunodeficiency virus (HIV), but 
also with hepatitis B virus (HBV) (Poynard et al, 2001). When compensated cirrhosis is 
established, the probability of decompensation is estimated to be 15-17 % within 2-3 years. 
The burden of expenses to health services due to HCV related disease has been predicted to 
be considerable in the future. In 2004, 23 % of all liver transplantations in Europe were 
related to HCV infection. Most likely the incidence of decompensated cirrhosis and HCC 
will increase substantially in the next few decades, due to the steady increase of HCV 
positive persons-at-risk (Lehman & Wilson, 2009). 
Chronic HCV infection is treated with a combination of pegylated interferon (peg-IFN)-ǂ, 
and the synthetic nucleoside analogue ribavirin. By this combination sustained virological 
response (SVR) is achieved in between 40 % and 50 % for genotype 1 and as high as 
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approximately 85 % for genotypes 2 and 3. Due to the limited success rate of this 
combined therapy approach, triple therapy options have been suggested. Thus, both 
protease inhibitors and polymerase inhibitors has been tested as addition to PEG-
interferon and ribavirin. These drugs are not approved by the authorities as standard 
treatment since they are still under investigation. Depending of the efficacy of triple 
therapy, the future need for liver transplantation may be reduced, with a considerable 
impact on health expenditures.    
Both viral and host factors are determinants for the spontaneous elimination or persistence 
of HCV. The high risk for chronic infection is most likely caused by a lack of a strong and 
specific immune response to viral antigens. On the other hand, an overly powerful immune 
response may lead to acute liver failure as seen in rare cases of hepatitis A and hepatitis B. 
The frequent mutations of HCV are challenging to the host immune response and results in 
a high risk for viral escape. In the recent years HCV research has been focused on the innate 
and adaptive response to the virus. Special attention has been put into the role of 
chemokines and their receptors which are responsible for recruitment of leukocytes from 
blood stream to the affected tissue. It has been proposed that this is one of the most critical 
immunological steps for an effective clearance of the virus. We have recently reported that 
in the antiviral treatment, SVR is dependent on a rapid (24 hours) chemokine response 
(Florholmen et al, 2011). This has initiated the present review of the immunological 
mechanisms against the HCV with a special emphasis on the chemokine response. 
2. Aims 
The first part of the chapter we will review the chemokine concept and its role in the HCV 
pathogenesis, their role in the innate and adaptive response to HCV leading to liver 
inflammation and liver fibrosis. The second part will concentrate on the chemokine response 
during antiviral treatment using interferon, ribavirin and the new nucleoside analogues.  
3. Hepatitis C virus 
HCV is a positive single stranded RNA virus with regions coding for structural peptides (an 
envelope, 9000 bases) and regions coding for non-structural (NS) peptides (1 – 5) (Myrmel et 
al, 2009). Eleven genotypes have so far been described and 6 are commonly diagnosed. The 
Genotypes 1, 4 and 6 respond to antiviral therapy (interferon (IFN) + ribavirin) with an SVR 
of 50 % and 85 %, respectively.  The virus has a high production of estimated 1012 virions 
per day, with an average half-life of 2.7 h and a turn-over rate close to 99 %. The calculated 
annual mutation rate is in the order of 1.5–2.0 x103 nucleotide substitutions per site. 
Furthermore, the virus has no proofreading mechanisms. The naturally occurring mutations 
may thereby enhance resistance both to endogenous immune responses and to anti-HCV 
therapy. Mutations conferring resistance of hepatitis C virus to the new treatment agents, 
the NS3 protease inhibitors, have been described (Halfon & Locarnini, 2011). The various 
genotypes have not been associated to specific pathobiology. As described above, however, 
the pattern of genotype related resistance to therapy has been extensively documented. The 
molecular mechanisms of this resistance have been described to some extent. Of great 
interest is the interferon sensitivity-determining region (ISDR) in the non-structural NSR5 
part of the virus genome. Amino acid substitutions in ISDR have been related to increased 
SVR of anti-HCV treatment (for review, see (Chayama & Hayes, 2011)).  
www.intechopen.com
Chemokine Responses to Hepatitis C Virus  
and Their Impact in Mediating the Treatment Responses of Antiviral Treatment 
 
143 
4. Antiviral immune response 
The immunological response to viral infection is a complex interplay between host tissue cells, 
the innate and adaptive immune responses. A series of mediators, systemic and paracrine, as 
well as cell-cell interaction will in most cases result in clearance of infection. Some viruses have 
developed strategies of immune evasion and can therefore establish chronic infections. In case 
of HCV infection, the resulting chronic inflammatory response is actually harmful to the host 
by driving development of fibrosis, cirrhosis, and liver failure or HCC. 
Viral pathogens can enter the host in several ways, the mucosal membranes being the most 
frequently used. A few viruses mainly spread via direct inoculation in the bloodstream, HCV 
being a classic example. Each type of virus has its preferred host cell type based on specific 
homing mechanisms. The HCV tropism for hepatocytes and internalization process is partly 
characterised and involve cluster of differentiation (CD) 81 and Claudin-1 (Thorley et al, 2010). 
Viral pathogens do not have metabolism and rely on modifying the host cell production 
apparatus to its own benefit. A range of defensive mechanisms has been developed in 
response to this strategy. The end result from these mechanisms is mostly death by lysis or 
apoptosis of the infected cell, while at the same time restricting spread of the infectious 
agent to neighbouring cells in the infected site. A short overview of the general immune 
response to viral infection with special emphasis on mechanisms related to the anti-HCV 
response will be given in the following.  
Leukocyte trafficking is a very important feature of the immune system allowing for the 
immune cells to patrol the entire host organism and thereby detect any intruding 
microorganism, bacteria or virus. The ability to generate a rapid local response when an 
intruder has been detected is based on homing mechanisms which mainly are triggered by 
early response cytokines and chemokines. As it turns out in the case of HCV infection, 
chemokines may also be central in generating an effective immune response following 
pharmacological intervention, as a swift chemokine response early in the course of 
treatment can predict a sustained virological response.  
4.1 Innate receptor systems 
The innate immune defence consists of several specialized cell types like dendritic cells 
(DC's) granulocytes, natural killer (NK) cells and macrophages. A common trait for these 
cell types is the pattern recognition receptors (PRR’s) consisting of both intracellular and 
transmembrane subtypes. The nucleotide oligomerization domain (NOD) receptors are 
intracellular and the toll like receptors (TLR’s) are transmembrane receptors primarily 
directed towards the extracellular compartment. These innate receptors detect common 
motifs from pathogenic microorganisms including both bacteria and viruses. Upon 
triggering the receptor an intracellular pathway common to most of the TLR’s involve 
myeloid differentiation primary response gene 88 (MyD88) and interleukin-1 receptor-
associated kinase (IRAK) kinases leading to activation of NF-κ-B and transcription of pro-
inflammatory cytokines.   
The professional antigen presenting cell i.e. dendritic cell carry an array of pattern recognition 
receptors and these cells are crucial for the initiation of an adaptive response. All cell lines of 
the adaptive system must be stimulated by DC’s in order to raise a response. The DC 
determines the profile of the adaptive system depending on its cytokine secretion pattern. 
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Most viruses have specific binding strategies for entry into host cells. This leads to a tropism 
of the virus rendering specific target cells its point of attack depending on the homing 
mechanism. Subsequently the virus particle is disassembled. At this point intracellular 
receptors may detect the pathogen and trigger production of early viral response cytokines – 
mainly type I interferons like IFN-ǂ and -ǃ. A possible trigger of IFN production can be 
double stranded RNA which has been found to stimulate type I interferons in vitro. 
Intracellular TLR3 is likely triggered by viral dsRNA.  
4.1.1 Interferons 
The family of interferons consists of three subgroups of mediators with high sequence 
homology. The first interferons were described by their physiological effects i.e. their ability 
to interfere with viral replication in cell cultures. The type I interferons is a group of five 
members: IFN -ǂ, -ǃ, -ω, -ǋ, and limitin. IFN-ǂ and IFN-ǃ can be secreted by practically all 
infected cells types following viral infection and the production of these cytokines is 
therefore not restricted to immune competent cells.  
Type I IFN has a common receptor IFN-ǂǃ-R which signals via the JAK-STAT pathway (JAK 
is short for Janus Kinase, and STAT is short for Signal Transducer and Activator of 
Transcription) towards the Interferon stimulated response element ISRE in the cell nucleus and 
induce transcription of several interferon inducible genes which in turn increase 
degradation of viral RNA and inhibit translation processes. The secreted interferon acts on 
both the secreting cell (autocrine stimulation) and neighbouring cells (paracrine stimulation) 
thus inhibiting local spread of the viral infection. Furthermore, interferons up-regulate 
major histocompatibility complex I (MHC-I) and thereby enhance the display of viral 
antigens to the adaptive effector cells (see below). Interferons also activate NK cells and 
thereby facilitate killing of infected cells. Thus, the entry of a virus in a cell induce 
production of interferons which in turn help protect neighbouring cells from infection but 
also facilitate killing of the infected cell by NK cells and/or antigen specific cytotoxic T cells.  
4.1.2 Natural killer cells 
NK cells are part of the innate immune response, and have an important role in combating 
viral infections in the early phase until the specific adaptive cytotoxic response is raised. The 
NK cell is believed to distinguish infected from normal cells via an intricate process 
involving both stimulatory and inhibitory signalling. A set of immunoglobulin-like 
receptors (Killer cell Immunoglobulin-like Receptors: KIR’s) and C-type lectins are involved 
in activation of the NK cell. A strong inhibitory signal is presentation of MHC-I on the cell 
surface which may be recognized by KIR’s or CD94:NKG2. As part of the microbial survival 
strategy many viral infections inhibit MHC-I display in order to restrain presentation of 
antigens to the adaptive response. This strategy removes the inhibitory signal to NK cells 
and the infected cells display only activation signals to the NK cells and will be eliminated. 
Some viruses induce conformational change of MHC-I with the same result. Thus, the NK 
cell may be able to detect the infected cell even if it evades the adaptive response by 
cytotoxic CD8+ T cells (see below).  
If stimulated by IFN-ǂ or IFN-ǃ the NK cell increase cytotoxic activity by a factor 20-100. 
The activated NK cell also secretes mediators important to direct the early response patterns 
in the tissue. The effector action of NK cells is completed by close binding to the infected cell 
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and may use different pathways including lysis of the cell membrane by perforins or 
triggering of apoptosis by interaction between Fas (CD95) and FasL (CD95L). The role of NK 
cells in HCV infection has been reviewed recently (Cheent & Khakoo, 2011). 
4.1.3 Adaptive immune response 
The adaptive immune response is antigen specific and can identify foreign antigens with 
great sensitivity and specificity. It consists of both humoral and cellular parts, of which 
especially the former can enhance the function of the innate response. Opsonising antibodies 
can boost the performance of innate phagocytes like neutrophil granulocytes and 
macrophages, and also enhance the function of an NK cell mediated cytotoxic response. The 
specific adaptive responses are modulated in phases: in the early response phase, activated 
cells undergo clonal expansion. This is followed by an effector phase where the strike 
against the microorganism is delivered. Finally the response is attenuated after elimination 
of the infectious agent – this phase is controlled by regulatory T cells (see below). In the 
process of down regulating the adaptive response, a small population of memory cells will 
remain dormant. These memory cells will be able to launch a swift and efficient adaptive 
response if the host should encounter the same agent at a later time.  
A common feature of the adaptive immune system is that the cells are unable to generate a 
response without help of the innate system or other parts of the adaptive response. The T 
cell receptor only recognizes its epitope in the context of an MHC molecule in combination 
with co-stimulatory factors. Each of the adaptive cell populations are restricted by specific 
mechanisms. T helper (Th) cells must be stimulated by their antigen presented on MHC-II 
by antigen presenting cells (APC’s). Cytotoxic T cells must be triggered by their epitope 
presented on MHC-I by the target cell. B cells bind their antigen on the B-cell receptor and 
internalize it for degradation and presentation on the surface by MHC-II. This allows for co-
stimulation by contact with, and cytokine secretion from, Th cells with the same specificity. 
In this way, the B cell can also present antigens for stimulation of Th cells. The local cytokine 
milieu at the time of stimulation determines which effector profile the stimulated Th cell 
will have: IFN- and interleukin (IL)-12A: Th1; IL-4: Th2; transforming growth factor-ǃ: Th3; 
IL-6 and TGF-ǃ: Th17; IL-10: T regulatory-1 (Tr1).   
In a viral infection, the adaptive immune response is triggered by presented antigens 
towards a classic Th1 profile enhancing a cytotoxic effector response. The cytotoxic CD8+ T 
cell is antigen specific in contrast to the NK cell, and stimulation of this cell line is primarily 
by Th1 cytokines like IFN-gamma and IL12A. The specificity rely on the T cell receptor 
recognition of the antigen as presented in the groove of a MHC-I molecule on the surface of 
the cell in question. Also, the cytotoxic T cell and the innate NK cell tend to mirror the Th 
profile in the immune response at hand, so these effector cells secrete cytokines and tend to 
enhance the milieu given by Th cells.  
The humoral part of the adaptive response also enhances the phagocyte and cytotoxic 
responses by a mechanism called opsonisation. Innate immune cells like neutrophil 
granulocytes, macrophages and NK cells carry receptors for the stem of the antibody (the FC 
part). Antibodies bind their target in the binding sites, and can crosslink the target to FC 
receptors on the innate cell. This way a viral particle on the surface of cells can be 
“visualized” to innate cells. Antibodies in blood, mucosal membranes, and the extracellular 
space also neutralise viral particles by binding.  
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4.1.4 Regulatory T cells 
The regulatory T cells include distinct subpopulations of which some are non-specific 
(CD25high natural Treg) and others are antigen specific (Tr1 and Th3). A common trait for 
regulatory T cells is the expression of forkhead family transcription factor FOXP3. The 
natural Treg’s are generated in the thymus and characterised by a high expression of CD25 
(IL-2 receptor). Natural Treg’s seem to act primarily by direct cell contact similar to the 
actions of NK cells. In contrast, the antigen specific regulatory T cells act by secretion of 
cytokines like IL-10 and TGF-beta. The regulatory cytokines and direct cell contact actions 
keep an important brake on the immune system in general, as an uncontrolled pro-
inflammatory response can lead to serious pathology and even organ destruction. Thus, 
the function of regulatory T cells is to balance the response of pro-inflammatory immune 
cells in order to keep homeostasis and avoid excessive tissue damage as well as resolving 
inflammation when the infection has been eliminated. The balance between pro- and anti-
inflammatory stimuli is delicate. The perfect immune response is swift, efficient, and 
causes a minimum of damage to host cells. Of course this is a compromise and the balance 
may tip in either direction. In HCV infection, an overly powerful response would lead to 
acute liver failure and death; it has been suggested that the development of cirrhosis in 
longstanding HCV infection is a result of an overly aggressive chronic inflammation 
(Larrubia et al, 2008). 
4.2 Homing and chemotaxis 
All of the cell types described above must be recruited to the site of infection in order to 
perform their part of the anti-microbial response. Though the adaptive humoral response 
and antibody production in most cases takes place in the regional lymph nodes, the B cells 
and Th cells must still be recruited and activated. The recruitment of leukocytes to the site of 
infection is an intricate process controlled by homing mechanisms. Some central 
mechanisms of leukocyte homing will be presented in the following.  
Chemotaxis is a basic behaviour seen in bacteria, primitive organisms, and several cell types 
in the immune system. The definition of chemotaxis is that the cell in question moves 
towards a higher concentration of a given chemotactic compound. As the name implies, 
chemokines are chemotactic compounds and a cell releasing chemokines will attract the 
attention of nearby immune cells.  
4.2.1 Chemokines 
The chemokines are a family of highly homologous small proteins with a common Greek key 
structure. These mediators have a key role in the earliest phases of infection. They can be 
released by many cell types in response to infectious agents and to physical damage. 
Chemokines can recruit cells of both innate and adaptive lines to the site of infection.  
The chemokines can be divided into two main subgroups: the CC group (at least 27 members 
named CCL1-28) with 2 adjacent cystein residues close to the amino-terminal, and the CXC 
group (at least 17 members named CXCL1-17) in which the two cystein residues are spaced by 
a single amino-acid. This structural difference is important because each subgroup has its own 
set of receptors. Some receptor cross-reaction within subgroup occurs, and each chemokine 
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may react with more than one of the receptors of the group. In addition to these main groups a 
few chemokines of C and CX3C group with their own receptor types have been described. 
4.2.2 Chemokine receptors 
The chemokine receptors have a common structure with a 7-transmembrane helix coupled 
to G-protein intracellular signalling. The subfamilies each have a set of chemokine receptors 
expressed on target cells. So far, ten CC receptors (CCR1-10) and seven CXC receptors 
(CXCR1-7) have been described. The system of chemokines and their receptors is quite 
complex and so far only partly described. However, at least theoretically, different 
chemokine secretion profiles combined with the receptor profiles of the target cells allow for 
close regulation of the homing process according to the infectious agent.  
4.2.3 Chemokine effects 
The chemokines trigger conformational change in the adhesion molecules (leukocyte 
integrins) on cell surface of leucocytes, thereby enabling a stable binding of the leukocyte to 
intercellular adhesion molecules (ICAM's) on the vessel wall. When the leukocyte is bound 
to the vessel wall it is able to squeeze between endothelial cells and enter the tissue. The 
cells first recruited are neutrophils, then later comes monocytes and immature dendritic 
cells. The chemokine activation also includes arming of the cells as effectors.  
4.2.4 Homing 
Upon chemokine activation endothelial cells present selectins and ICAM’s on the luminal 
surface. Leukocytes tend to roll along the endothelial surface due to weak binding between 
endothelial selectin and leukocyte sialyl-Lewisx (s-Lex) blood group antigen. If the leukocyte 
integrin profile matches the ICAM a strong binding is established. This binding is enhanced 
further by conformational changes in the leukocyte integrin triggered by chemokine 
stimulation. When the cell is tightly bound, extravasation by diapedesis can be initiated. After 
extravasation, further movement along a chemotactic gradient to the site of infection follows. 
The endothelial cells will be further activated by early response cytokines like tumor 
necrosis factor (TNF)-ǂ. The chemokine activation of the neutrophil granulocyte will also 
stimulate the oxidative burst, which is a characteristic of the effector profile in this cell type.   
4.2.5 Chemokines in the adaptive immune response 
Certain chemokine receptors are expressed in certain immune profile cells. Thus a Th1 
chemokine receptor set can be defined: CCR5 and CXCR3; while CCR3, CCR4 and CCR8 are 
linked to Th2 responses (Larrubia et al, 2008). Therefore, in a viral infection a certain subset 
of chemokines are especially interesting, as the Th1 response is considered the adequate and 
efficient response type. Ligands for the CXCR3 (Interferon gamma induced protein 10 (IP-
10), Monokine induced by gamma interferon (Mig), Interferon-inducible T-cell alpha 
chemoattractant (I-TAC)) and CCR5 (Regulated on Activation, Normal T Expressed and 
Secreted (RANTES), macrophage inflammatory protein (MIP)-1-alpha, and MIP-1-beta) are 
theoretically crucial for the initiation of response and resolution of infection. Indeed, a frame 
shift mutation on the CCR5 receptor increases susceptibility to HCV infection (Woitas et al, 
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2002). In effect, both theoretical and experimental data support the crucial role of the 
chemokine response for mounting an efficient resolution of the viral infection.  
4.3 Special immunobiological features of the liver 
The liver is an immunotolerant organ with constitutive high expression of IL-10 and TGF-ǃ 
(Crispe et al, 2006; Manigold & Racanelli, 2007). The sinusoids are inhabited by a special 
type of ‘pit cells’; large granular lymphocytes of the NK cell trait. Data from mouse studies 
indicate that the NK cells of the liver tend to secrete more regulatory cytokines and less pro-
inflammatory cytokines than their peripheral counterparts (Cheent & Khakoo, 2011; Lassen 
et al, 2010). When the HCV virus enters this environment, a proper immune response must 
be launched, and to this end a massive recruitment of different types of immune cells is 
needed. Cells of the innate immune system such as dendritic cells and NK cells are 
important for the initial response and stimulation of a proper adaptive Th1 response 
including antigen specific T helper cells, cytotoxic T cells and B cells as well as inducible 
regulatory T cells. All of these cell types must be recruited from the circulation and to this 
end an array of chemotactic signals are activated.  
Chemokines have local effects on endothelium activating processes for trans-endothelial 
migration, and the leucocytes also have chemokine receptors activating leukocytes rolling 
and binding of selectins to integrin receptors. Thus chemokines have an important role in 
infection response allowing extravasation of leucocytes to the site of infection. As the liver 
has some inherent immunetolerance as mentioned above, this recruitment of external cells is 
especially important. Furthermore, considering the treatment of HCV with peg-IFN-ǂ and 
Ribavirin the therapy may be efficient by altering the profile and composition of 
inflammatory cells in the liver. In this respect, the leukocyte recruitment seems have a key 
role in resolution of the infection.  
4.3.1 Immune response to HCV infection 
HCV has parenchymal liver cells as primary target utilizing CD81, claudin-1, and possibly 
the LDL receptor. After binding of to a target cell, the viral particle is internalized and 
disassembled in the cytoplasm. HCV virus has developed strategies to evade some of the 
basic antiviral mechanisms described above. The early IFN-ǃ response can be blunted by 
cleaving adaptor proteins necessary for activating IFN transcription, and can also inhibit the 
JAK-STAT pathway thus inhibiting the intracellular effector events after stimulation by  
IFN-ǂ.  
Relatively recently a new series of ǌ-interferons have been described. These include the 
highly homologous IL-28A (IFN-ǌ-2), IL-28B (IFN-ǌ-3) and IL-29 (IFN-ǌ-1). Especially IL-28B 
has turned out to be interesting in regard to HCV infection. It seems that a firm IL-28B 
response is necessary for viral clearing, and that CC genotype in the rs12979860 single 
nucleotide polymorphism (SNP) (The Duke) in the promoter of the IL-28B gene is associated 
with a higher rate of spontaneous resolution of infection and also can predict response to 
treatment with peg-IFN-ǂ (Langhans et al, 2011). 
4.3.2 Chemokines in the context of HCV infection 
Considering the immunotolerant milieu of the liver, an efficient immune response against a 
pathogen like HCV must be based on a considerable influx of fresh immune cells. In this 
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respect, the chemokine response is crucial and may be one of the main factors that 
determine if the infection becomes chronic or is spontaneously resolved. One of the effects 
of peg-IFN-ǂ therapy is to increase the pro-inflammatory response including the chemokine 
response allowing for fresh Th1 cells, B cells, NK cells, and dendritic cells to engage the 
virus. As such, the chemokine response can be seen as a common marker for a step-up in the 
immune response in initiation of treatment. Whether observed chemokine responses are 
directly triggered by the peg-IFN-ǂ or result from a general increase in immunologic activity 
in the liver remains to be determined. However, as a biological marker of sustained 
virological response, the early rise in chemokine activity is interesting.  
5. Treatment of hepatitis C 
As described in the Introduction, peg-IFN-ǂ in combination with the nucleoside analogue 
ribavirin is the standard treatment of HCV infection. Upcoming new drugs are albumin-
INF-ǂ, and nucleoside analogues or protease inhibitors, and nucleoside analogue/non-
nucleoside analogue polymerase inhibitors. In general, these agents act via inhibitory 
mechanisms on the HCV gene to reduce the viral replication. These new anti HCV drugs 
exert their effects directly on the virus replication:  protein kinase inhibitors on NS3A/B and 
polymerase inhibitors on NS5A/B (for review, see (Vezali et al, 2011)).  
5.1 IFN-α  
The mechanisms of action of peg-IFN-ǂ are through indirect activating of the immune 
system and a direct antiviral mechanism at the interferon-sensitive sites of the HCV 
inhibiting the transcription. These mechanisms of action are rather complex and beyond the 
scope of this presentation. Briefly, peg-INF-ǂ triggers a cascade of intracellular events 
including activations of IFN-inducible genes and increased synthesis of IFN-induced 
proteins (Katze et al, 2002). These proteins such as RNA-dependent protein kinase inhibit 
intracellular virus replication by a RNA-degrading mechanism. Peg-IFN-ǂ also inhibits the 
viral replication indirectly via an immune response and most likely via activation of 
immune cells. These are complex mechanisms such as increased MHC-I expression and 
activation of immune cells with cytokine secretion. Finally, peg-IFN-ǂ also induces an 
immuno-modulation in the favour of a Th1 response and an inhibition of a Th2 response 
(see fig 1, for review, see (Vezali et al, 2011)).  
5.2 Ribavirin  
The exact mode of action of ribavirin is unknown. As ribavirin alone does not inhibit the 
virus replication, a synergistic action together with IFN-ǂ has been proposed. The proposed 
mechanisms of actions of ribavirin are: 1. an indirect host change of Th profile from a Th2 to 
a Th1 profile. 2. A direct inhibitory effect on the NS5B encoded RNA dependent RNA 
polymerase (for review, see (Lau et al, 2002)) (figure 1) 
6. Chemokines in antiviral therapy 
As described above, the chemokines play a pivotal role in the chemotactic immune response 
to HCV by acting via their specific receptors on immune active cells. The role of chemokines 
in the antiviral treatment is so far only incompletely understood. Of special interest for the  
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Fig. 1. Targets for antiviral therapy. 
hepatic immunity is the CC chemokines macrophage inflammatory protein (MIP) - (CCL3), 
MIP-1 (CCL4) and Regulated on Activation, Normal T Expressed and Secreted (RANTES) 
(CCL5). These chemokines are expressed by the portal vessel endothelium and recruit 
macrophages and lymphocytes into the liver (Ahlenstiel et al, 2004; Kusano et al, 2000). In 
the following we present the role of chemokines at baseline and as an early predictor of 
antiviral responses and clearance of the virus. 
6.1 Chemokines at baseline    
In one small sample sized study baseline levels before anti-HCV treatment serum levels of 
MIP-1 could predict a significant effect on SVR, but not eotaxin, MIP-1, RANTES 
(CCL5) and IL-8 (Yoneda et al, 2011). Serum levels of MIP-3 (Yamauchi et al, 2002) have 
also been associated with a positive prognostic response. Moreover, increase of CXCR3 
expressing CD8+ cells during treatment has been associated with achievement of viral 
control (Larrubia et al, 2007). Of interest was that a substitution in the ISDR was 
associated with response to treatment. In contrast, another study showed that baseline  
IL-8 level was inversely related to the response to therapy i.e. the higher IL-8 levels, the 
lower chance of SVR (Akbar et al, 2011). In a broad screening study of baseline CCL and 
CXCL chemokines, only CXCL10 was significantly associated to lack of SVR (Moura et al, 
2011). In another study high CXCL10 gene expression during treatment (Sixtos-Alonso et 
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al, 2011) and plasma level (Moura et al, 2011) were negative predictors of SVR. Finally, in 
two other studies baseline levels of IP10 were associated with a negative prognostic 
response to treatment with peg-IFN-ǂ and ribavirin (Butera et al, 2005; Lagging et al, 
2006). Interestingly, as the CCL 3-5 are produced in the portal vascular endothelium while 
IP-10 is produced mainly in sinusoidal endothelium and hepatocytes surrounding lobular 
inflammation (Zeremski et al, 2007).  
 
 
 
 
 
 
Fig. 2 Early serum chemokine responses to the treatment of chronic HCV infection. 
(Florholmen et al, 2011) 
It is hard to interpret these apparent contradictional results of how chemokine levels can 
predict the response to treatment. It is of interest to note that the chemokines predicting an 
effective viral clearance are the CC-chemokines expressed by the portal vessel endothelium. 
The other chemokines predicting a lack of effect of antiviral treatment are recruited from 
other sources. These chemokines reflect an apparent state of viral resistance, but further 
studies are needed to reveal the mechanisms of action. 
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6.2 Early chemokine response  
It is expected that an initial strong immune response is critical for a successful viral 
clearance in the anti HCV treatment. As far we know only one study have investigated early 
(24 hrs) chemokine responses during anti-HCV treatment. An early response of MIP-1, 
MIP-1, and RANTES may predict a sustained virological treatment response. MCP-1 was 
significantly increased but could not discriminate between SVRs and non-SVRs (Fig. 2) 
(Florholmen et al, 2011). However, the receiver-operator characteristic (ROC) analyses for 
MIP-1, MIP-1 shows that alone, these chemokines are not suitable for clinical decisions 
like termination of therapy due to probable non-response (Fig. 3). Therefore, this study 
indicates that an early response of chemokines can be critical for an effective virus clearance 
during the anti-HCV treatment.   
The chemokine studies mentioned above have to be interpreted with some caution both due 
to small sample sizes and that none of them were designed for prognostics and stratified for 
confounding factors.  
 
 
 
 
 
Fig. 3. ROC analysis of early chemokine response as predictor of sustained virological 
response (Florholmen et al, 2011). 
7. New antiviral agents 
The new antiviral agents based on inhibition of proteases and polymerases exert their effects 
on the various NS regions of the HCV genome described above. Ribavirin also has effects on 
an indirect mechanism of host T-cell mediation with a change from a Th2 to a Th1 profile. So 
far there is no evidence that the new antiviral drugs have direct suppressive effects on the 
HCV. Experiences from treatment of HIV show that there is a need of combination of two or 
more therapeutical molecules to prevent development of resistant HCV strains. So far there 
is an increase of SVR from 40-50 % to 75 % going from duo-therapy to triple-therapy of 
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patients with HCV genotype 1. It would be of great interest to know if the new triple-
therapy is dependent on an additional chemokine-based viral clearance for an effective 
treatment response. Therefore, we are waiting for further studies.   
8. Concluding remarks 
Chemokines seem to play a pivotal role in the immune response to HCV both to induce a 
spontaneous clearance during an active infection but also during the immunotherapy with 
peg-IFN-ǂ and ribavirin. The mechanisms of action of chemokines are complex and still far 
from being fully understood. The understanding of both the successful treatment and the 
apparent resistance mechanisms with a virus escape from the chemokines and other 
immune factors is still incomplete. Most of the CC chemokines seem to play an important 
role in the anti virus attack. However, for other chemokines including some CXC-
chemokines, increased secretions represent an apparent state of antiviral resistance to 
therapy. This paradox is so far poorly understood, but different compartments of chemokine 
production for the CC and the CXC chemokines may be a clue. It seems that the CC 
chemokines located in the portal vein may play a pivotal role for en effective clearance of 
the HCV, and the early chemokine response during antiviral treatment may be used as 
prognostic biomarkers. However, most of all there is a need of future studies relating viral 
kinetics to the chemokine responses in vivo, experimental in vitro models may contribute to 
a more comprehensible understanding of the role of chemokines in HCV infection.   
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